Erratum to: Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with *KIT* exon 11 mutation

Yoon-Koo Kang · Byung Woog Kang · Seock-Ah Im · Jae-Lyun Lee ·
Sook Ryun Park · Won Ki Kang · Heung Moon Chang · Tae Won Kim ·
Do-Youn Oh · Kyung Hae Jung · Min-Hee Ryu

Published online: 13 January 2013
© Springer-Verlag Berlin Heidelberg 2013

Erratum to: Cancer Chemother Pharmacol (2013)
71:43–51
DOI 10.1007/s00280-012-1970-3

Unfortunately, Fig. 3b, c were inadvertently swapped in the online published article. The correct version of Fig. 3 is placed in the following page.

The online version of the original article can be found under doi:[10.1007/s00280-012-1970-3](https://doi.org/10.1007/s00280-012-1970-3).

Y.-K. Kang (✉) · B. W. Kang · J.-L. Lee ·
H. M. Chang · T. W. Kim · M.-H. Ryu
Department of Oncology, University of Ulsan College
of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil,
Songpa-gu, Seoul 138-736, Korea
e-mail: ykkang@amc.seoul.kr

S.-A. Im · D.-Y. Oh
Department of Internal Medicine, Seoul National University
Hospital, Seoul National University College of Medicine,
28 Yongon-Dong, Chongno-Gu, Seoul 110-744, Korea

S. R. Park
Center for Gastric Cancer, Research Institute and Hospital,
National Cancer Center, 809 Madu1-dong, Ilsandong-gu,
Goyang-si, Gyeonggi-do 411-769, Korea

W. K. Kang
Department of Medicine, Sungkyunkwan University School
of Medicine, Samsung Medical Center, 50 Irwon-dong,
Kangnam-gu, Seoul 135-710, Korea

K. H. Jung
Center for Colorectal Cancer, Research Institute and Hospital,
National Cancer Center, 809 Madu1-dong, Ilsandong-gu,
Goyang-si, Gyeonggi-do 411-769, Korea

Present Address:

K. H. Jung
Department of Oncology, University of Ulsan College
of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil,
Songpa-gu, Seoul 138-736, Korea

Present Address:

B. W. Kang
Department of Hematology/Oncology, Kyungpook National
University School of Medicine, Kyungpook National University
Hospital, 474, Hakjeongdong, Buk-gu, Daegu 702-210, Korea

Fig. 3 Kaplan–Meier analysis of recurrence-free survival: **a** according to group categorization by size and mitotic count, **b** according to the type of *KIT* exon 11 mutations, **c** according to the site of primary tumor